Surgery Websites
Thoracic Oncology Program »  Meet the Team »  Thoracic Surgeons »  Michael Mann, M.D.
Michael Mann, M.D., FACS

Michael Mann, M.D., FACS

Professor of Surgery
Division of Adult Cardiothoracic Surgery

Contact Information

(415) 885-3882  Appointments
(415) 353-9525  Clinic Fax
(415) 353- 7502 Academic Office  
Open Popup
  • 1981-85, Princeton University, A.B. , Chemistry
  • 1985-91, Stanford University, MD , Medicine
  • Stanford University, Intern, Surgery
  • Stanford University, Resident, General Surgery
  • Brigham and Women's Hospital/Harvard Medical School, Resident, General Surgery
  • University of California, San Francisco School of Medicine, Resident, Cardiothoracic Surgery
  • Stanford University, Postdoctoral Fellow
  • NIH Ruth L. Kirschstein National Research Service Award (NRSA) Research Training Fellowship, Cardiovascular Disease
  • American Board of Surgery
  • American Board of Thoracic Surgery
  • Thoracic Oncology Program
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • Heart and Lung Transplantation Program
  • UCSF Cardiovascular Research Institute
  • Biomarkers and molecular profiling of metastasis
  • Cardiovascular cell cycle biology
  • Cardiovascular tissue engineering
  • Clinical management of pulmonary metastasis
  • Clinical management of sarcoma
  • Evolving techniques for minimally invasive chest surgery
  • Molecular and stem cell biology
  • Molecular biology of metastasis
  • Molecular biology of sarcomas
  • Molecular genetics of heart disease
  • Myocardial gene therapy
  • Personalized Medicine
  • Stem and progenitor cell transplantation for cardiovascular regeneration
  • Therapeutic neovascularization for ischemic disease
  • Mandarin

Michael Mann, M.D. joined the Thoracic Oncology Program in 2003 as a cardiothoracic surgeon. He received his M.D. from Stanford University and was awarded a  Ruth L. Kirschstein National Research Service Award (NRSA) Research Training Fellowship through the NIH. Dr. Mann completed his General Surgery residency at Brigham and Women's Hospital/Harvard Medical School and his Cardiothoracic Surgery fellowship at UCSF.

His areas of expertise include lung cancer, mesothelioma, esophageal cancer, sarcoma and minimally invasive (video-assisted) thoracoscopic surgery. He also has expertise in performing cardiac procedures including coronary bypass, valve replacement, and aortic reconstruction.

Dr. Mann is widely admired for his teaching skills and is Assistant Director of the Thoracic Surgery Training Program.  He holds memberships in numerous professional organizations including the Society of Thoracic Surgeons, American College of Surgeons, American Heart Association, American College of Cardiology and the Massachusetts Medical Society. Highly respected by his peers, Dr. Mann was named to the list of U.S. News "Top Doctors," which denotes the top 10% of physicians within a region practicing a given specialty. He has received numerous awards including the Cardiovascular Medicine Award for Excellence in Research, Dean's Award for Excellence in Research, and William Randolph Hearst Endowment for Young Investigators. Dr. Mann also serves as a scientific reviewer for numerous professional journals.

While on the faculty at Harvard Medical School, Dr. Mann founded the Cardiovascular Gene Therapy Group. He also invented  several novel drug and delivery technologies and helped pioneer the application of gene regulation and vascular biology principles to the problem of coronary bypass graft failure. This led to one of the first large scale programs to evaluate the integration of molecular therapy into cardiac surgery.

Dr. Mann's research in genetic and molecular therapies has been widely recognized. He is currently an Associate Investigator in the UCSF Cardiovascular Research Institute. Dr. Mann also serves as a scientific advisor to the American Heart Association, the NIH Recombinant-DNA Advisory Committee, and to numerous device and pharmaceutical companies.

The Cardiothoracic Translational Research Laboratory is focused on turning a deeper understanding of the complex biology of cancer and heart failure into a new generation of cellular and molecular therapies. The lab's cancer research focuses on untangling the mystery of metastasis, a pathologic phenomenon that remains both poorly understood and still responsible for most cancer deaths. Heart failure, in turn, affects more than 5 million Americans and is already the greatest single economic burden in American health care, yet no existing therapies can either halt or reverse the disease process.

Michael J. Mann, M.D. is the Lab Director. His group is analyzing the molecular basis of metastasis to the lungs through careful analysis of human tumor specimens. Via comparison of the complex molecular responses of both primary cancers in their original locations and metastatic lesions in the same patients, they have begun to reveal a pattern of gene activity that may yield both more precise diagnosis of and revolutionary new therapies for metastatic disease.
The Cardiac wing of the Translational Research Lab has been studying the molecular underpinnings of heart failure over the past decade, and has made several fundamental observations regarding the balance of molecular signals that can push a heart either toward compensatory adaptation or relentless failure. By combining cutting edge reconstructive surgery with novel molecular intervention, the group hopes to provide a strong scientific foundation for the clinical development of unprecedented human therapies.

Data provided by UCSF Profiles, powered by CTSI
  • ERK Signaling and a Hybrid Surgical/Molecular Approach for Chronic Heart Failure
    Sponsor ID:
    Funding Period:
    Dec 2005
    Apr 2017
    Principal Investigator
  • The role of S1P signaling in surgical cardiac remodeling
    Sponsor ID:
    Funding Period:
    Apr 2006
    Mar 2012
    Principal Investigator
    Sponsor ID:
    Funding Period:
    Oct 1993
    Jan 0001
    Principal Investigator
Data provided by UCSF Profiles, powered by CTSI
  1. Gavitt A. Woodard, Johannes R. Kratz, Greg Haro, Matthew A. Gubens, Collin M. Blakely, Kirk D. Jones, Michael J. Mann, David M. Jablons. Molecular risk stratification is independent of EGFR mutation status in identifying early stage non-squamous non-small cell lung cancer patients at risk for recurrence and likely to benefit from adjuvant chemotherapy. Clinical Lung Cancer. 2021 Aug 1. View in PubMed
  2. G. Woodard, J. Kratz, G. Haro, M. Gubens, C. Blakely, K. Jones, M. Mann, D. Jablons. MO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy. Journal of Thoracic Oncology. 2021 Jan 1; 16(1):s21. View in PubMed
  3. Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer. JAMA Netw Open. 2019 12 02; 2(12):e1917062. View in PubMed
  4. G. Woodard, V. Ding, I. Kim, K. Jones, G. Chavez, G. Haro, J. Kratz, M. Mann, J. Rotow, C. Blakely, D. Jablons. MA06.09 Timing of Driver Mutation Development and the Genetic Evolution of Semi-Solid Lung Nodules into Early NSCLC. Journal of Thoracic Oncology. 2019 Oct 1; 14(10):s271-s272. View in PubMed
  5. G. Woodard, V. Ding, I. Kim, K. Jones, G. Chavez, G. Haro, J. Kratz, M. Mann, J. Rotow, C. Blakely, D. Jablons. MA06.09 Timing of Driver Mutation Development and the Genetic Evolution of Semi-Solid Lung Nodules into Early NSCLC. . 2019 Oct 1; 14(10):s271-s272. View in PubMed
  6. View All Publications


Site Directory